TITLE: Hepatocellular Carcinoma: therapeutic approaches in a modern era.

Aims & Scope:

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide, it is the fifth most common cancer and the third most important cause of cancer related mortality in men. In recent years, the management of HCC has radically changed, because of improved diagnostic capacity, the development of evidence-based staging systems, and the availability of more effective treatments. Nevertheless, HCC has been proven to be less susceptible to chemotherapy as compared to other neoplasms.

Thus in this special theme issue we want to focus on HCC. We aim to give a comprehensive overview of this neoplasm, including recent changes in the oncological management with the application of targeted chemotherapy. This theme issue aims to provide the clinicians of a tool able to guide in the diagnosis and in the treatment of HCC. In fact, in a modern era, great importance should be given to the tumor genetic expression profile and pathological feature so as to predict survival and, thus, to tailor the best treatment for each patient.

We want to give an overview of the applicability of m-Tor inhibitor immunosuppressive therapy after Liver Transplantation and its role in preventing HCC recurrence and to explore the oncological value of robotic resection for HCC.

We also will focus on the oncological treatment of HCC recurrence after liver transplantation.

Key words: Hepatocellular carcinoma, prognostic factors of survival, recurrence, liver resection, liver transplantation, multimodal approach.

Subtopics:

1. Impact of expression profiling of Hepatocellular Carcinoma on the natural history and on the therapeutic choice.
3. Oncological value of Robotic Liver Resection: Is it worthy?
4. Multimodal oncological approach in patients affected by recurrent Hepatocellular Carcinoma after Liver transplantation.
5. Oncological impact of m-Tor inhibitor immunosuppressive therapy after Liver Transplantation for Hepatocellular Carcinoma: review of the literature.
6. The evolving role of local treatment in the management of Hepatocellular Carcinoma in the third millennium.
Contributing Authors:

1. **Fabrizio Di Benedetto**, MD PhD. Hepato-pancreato-biliary Surgery and Liver Transplantation Unit. University of Modena and Reggio Emilia. Modena, Italy.


4. **Massimiliano Berretta**, MD PhD. Department of Medical Oncology National Cancer Institute of Aviano (PN) Italy.

Schedule:

Manuscript submission deadline: 20 September 2015

Peer Review Due: 20 October 2015

Revision Due: 10 November 2015

Notification of acceptance by the Guest Editor: 30 November 2015

Final manuscripts due: 8 December 2015